# Evan Y. Yu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/evan-y-yu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,184 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 60 |
| i10-index | 191 |
| OpenAlex ID | https://openalex.org/A5084909001 |
| ORCID iD | https://orcid.org/0000-0002-1510-8044 |
| Works | 577 |

## Researcher papers

- [Integrative Clinical Genomics of Advanced Prostate Cancer](https://scholariq.org/papers/integrative-clinical-genomics-of-advanced-prostate-cancer/)
- [Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy](https://scholariq.org/papers/abiraterone-in-metastatic-prostate-cancer-without-previous-chemotherapy/)
- [Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-alone-or-combined-with-chemotherapy-versus-chemotherapy-as-first/)
- [Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer](https://scholariq.org/papers/multicenter-assessment-of-neoadjuvant-chemotherapy-for-muscle-invasive-bladder/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-in-patients-with/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies-2/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.